Barr Labs
Executive Summary
FDA notifies the Pomona, N.Y.-based generic drugs company Sept. 19 of its compliance with current Good Manufacturing Practices after inspections of Barr's Northvale, N.J. and Pomona facilities. Barr will now be able to receive approval for over 10 pending ANDAs and supplements for products not currently marketed. The company says it will bring back only those products that are economically significant. Barr undertook a revalidation program and has since reintroduced more than nine products under FDA validation requirements. The company had to suspend production of 24 products in February 1993 following litigation with FDA